FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: TempraMed Technologies Ltd. (the "**Issuer**").

Trading Symbol: VIVI

Number of Outstanding Listed Securities: 79,006,497

Date: July 3, 2026

Report on Business

1. Provide a general overview and discussion of the development of the Issuer's business and operations over the previous month. Where the Issuer was inactive disclose this fact.

General Overview - The Issuer is focused on the development and marketing of devices that provide temperature protection and "SMART" data collection capability for medications and other substances.

Its primary operations are all located in Israel while most sales activities are in the USA. Both B2B and direct to consumer.

To date the issuer has sold more than 125,000 devices worldwide of both VIVI Cap for insulin and GLP-1 and VIVI Epi- for the legacy Mylan EpiPen. Sales of these products continue through B2B and B2C channels while the company works to expand its B2B channels.

launch "VIVI Cap Smart" and the "Smart Cover" add-on, for the existing installed base of VIVI Cap users was done before year end.

Additionally, the issuer launched VIVI Med for vials and biologics and a modified VIVI Epi that fits the legacy Mylan EpiPen shape as well as Adrenaclick shape pen.

The Issuer has opened an additional U.S. manufacturing facility in Florida. The additional site expands the Company's operational capacity and enhances its ability to serve the rapidly growing demand for TempraMed's temperature-stable medication-storage devices across the United States and globally.

The issuer has entered a strategic media partnership with Dr. Phil's envoy media.

Listing –

On October 15, 2025, The Issuer common shares started trading on the CSE under the trading symbol "VIVI".

During November 2025, The Issuer common shares started trading on the Frankfurt stock exchange under the trading symbol "9DY"

During June 2026, The Issuer common shares started trading on the OTCID under the trading symbol “TMPTF”

Financing – N/A.

The Issuer has engaged Plutus Invest & Consulting GmbH (“Plutus”) to provide certain marketing services in connection with the Company’s listing on the Frankfurt Stock Exchange for a period of twelve (12) months, commencing on June 1, 2026. This arm’s length Agreement will provide the Company with marketing services that include, among others, the information distribution, media distribution, IR management etc. with an objective to generally bring attention to the business of the Company to the German market (“the Program”).

The Company has agreed to pay Plutus a total fee of €100,000 (approximately CAD $160,000), which will be paid in advance for the entirety of the program.

2. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

N/A.

3. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

No products or services were discontinued in June 2026.

4. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

The issuer signed an agreement with Mobil Saúde Comercial Ltda ("Mobil Saúde") regarding the exclusive distribution of TempraMed products in Brazil. The arrangement contemplates a three-year exclusive distribution framework with minimum annual purchase commitments, reflecting the parties' expectation of growing market demand. Exclusivity would become effective following placement and full prepayment of the initial order.

The issuer signed a non-binding letter of intent ("**LOI**") dated June 16, 2026 with Rawafed Health International Company ("**Rawafed**"), a leading healthcare distribution company with broad reach across pharmacy networks and healthcare infrastructure in the Kingdom of Saudi Arabia. The LOI provides a pathway to entering into an exclusive distribution of TempraMed products in the Kingdom of Saudi Arabia

The LOI sets out the principal terms under which the parties intend to negotiate and enter into the Proposed Distribution Agreement, which provides for a 5-year distribution arrangement within Saudi Arabia, with exclusivity requiring minimum purchase orders from Rawafed of approximately US$3.1 million over the 5-year period. The LOI contemplates the Proposed Distribution Agreement to include performance review mechanisms, along with Rawafed providing regulatory and market-development support; however, there is no guarantee the Company and Rawafed will enter into the Proposed Distribution Agreement on the terms contemplated by the LOI or at all.

The issuer announced the expansion of its relationship with McKesson Medical-Surgical ("MMS"). The agreement, dated June 23, 2026, broadens the scope of collaboration to include full portfolio distribution across North America, enhanced B2B capabilities, and deeper integration into one of the largest healthcare marketplaces in the United States.

5. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer's affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

   No expiry or termination of any material contracts or agreements during June 2026.

6. Describe any acquisitions by the Issuer or dispositions of the Issuer's assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

   No acquisitions by the Issuer or dispositions of the Issuer's assets during June 2026.

7. Describe the acquisition of new customers or loss of customers.

   N/A

   .

8. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

9. hirings, terminations or lay-offs with details of anticipated length of lay-offs.

   None.

10. Report on any labour disputes and resolutions of those disputes if applicable.

    None.

11. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

    None.

12. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

    None.

13. Provide details of any securities issued and options or warrants granted.

    425,792 common shares were issued following the vesting of RSUs.

    200,000 RSUs were granted to a consultant.

14. Provide details of any loans to or by Related Persons.

    None.

15. Provide details of any changes in directors, officers or committee members.

    None.

16. Discuss any trends which are likely to impact the Issuer including trends in the Issuer's market(s) or political/regulatory trends.

    None.

Certificate Of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated: July 3, 2026.

Gabriel Kabazo
Name of Director or Senior Officer

/S/ "Gabriel Kabazo"
Signature

CFO
Official Capacity

Issuer Details Name of Issuer TempraMed Technologies Ltd.	For Month End June 30, 2026	Date of Report July 3, 2026
Issuer Address 504-9300 Parksville Drive		
City/Province/Postal Code Richmond, B.C. V7E 4W2	Issuer Fax No. N/A	Issuer Telephone No. (604) 833 6820
Contact Name Gabriel Kabazo	Contact Position CFO	Contact Telephone No. (604) 833 6820
Contact Email Address gkabazo@gmail.com	Web Site Address https://tempramed.com/	